Tag Archives: digital-marketing

RESI IPC Winner VerImmune Advances a New Immuno-Oncology Playbook  

18 Feb

VerImmune is an emerging biotechnology company advancing a novel virus-inspired platform designed to redirect the body’s existing immune memory toward hard-to-treat diseases. The company participated in RESI JPM as part of the Enterprise Singapore delegation, reflecting Singapore’s growing role as a global hub for biomedical innovation and cross-border collaboration. In this conversation, Founder & CEO Joshua Wang shares insights into VerImmune’s scientific approach, clinical ambitions, and momentum following recognition as an Innovator’s Pitch Challenge (IPC) winner. 

Joshua Wang
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): For readers who are just discovering VerImmune, how do you describe the company and its scientific focus? 

Joshua Wang (JW): VerImmune is an IND-enabling stage biotechnology company leveraging the natural architecture of viruses to create a self-assembling Virus-inspired Particle (ViP™) platform for targeted therapeutic delivery of diverse payloads for oncology, autoimmunity, and animal health indications

VerImmune’s lead ViP program, VERI-101, is pioneering a new First-in-Class immuno-oncology paradigm that repurposes existing CMV-specific T-cell memory cells (present in ~85% of adults globally) to recognize and eliminate solid and metastatic tumors in a tumor-type-agnostic manner, either as a monotherapy or in combination with existing standards of care.

CD: What unmet medical need are you targeting, and how does your platform or approach differentiate you in the immunology landscape? 

JW: Despite recent blockbuster innovations like checkpoint inhibitors (PD-1/PD-L1) , antibody drug-conjugates and radioligand therapies, resistance to these treatments and other standards-of-care becomes inevitable and cancer recurs. This inevitably creates a large population of post-failure patients with limited to no options.
Hence, the biggest unmet need in oncology remains dealing with such cancer resistance and recurrence.

VerImmune has discovered that within these patient populations, regardless of previous treatment, most patients still retain a robust immunity to viruses.

VerImmune targets this preserved anti-viral immune memory and repurposes it against tumors, bypassing previous mechanisms of immune or genetic resistance.

Since all patients have pre-existing viral immunity (e.g to CMV which is what VERI-101 targets), VerImmune’ s approach represents a distinct and potentially category-defining modality in immuno-oncology, with clear strategic and partnering value in the post-failure setting and most importantly, giving patients one more shot at a treatment opportunity!

CD: What was your experience participating in the Innovator’s Pitch Challenge at RESI JPM? 

JW: As part of the Enterprise Singapore startup delegation from Singapore, participating at the Innovator’s Pitch Challenge at JPM RESI 2026 was a high-impact international opportunity as it occurred alongside 90+ other companies from around the world in a forum with concentrated investor and partner visibility. We were truly honored to win 2nd place which provides further external validation of our science, platform, and commercialization strategy before a global audience.

CD: With so many strong companies presenting, what feedback or reactions stood out to you from judges or attendees? 

JW: Despite a challenging biotech financing environment, which does not favor highly novel new mechanisms and approaches, we were encouraged that judges and attendees acknowledge the strategic logic that the post-PD1/ADC/RLT failure population still retains active anti-viral immunity. They highlighted the novelty of redirecting intact, non-exhausted viral immune memory rather than attempting to generate new anti-tumor immunity or introduce another small-molecule payload, viewing it as a differentiated and refreshing timely approach.

CD: How has RESI JPM helped advance investors, partners, or industry conversations for VerImmune? 

JW: Yes, being recognized as a winner has amplified the visibility of VerImmune’s approach and strengthened its perceived credibility. It has led to increased inbound interest from investors seeking to learn more, rather than relying primarily on outbound outreach.

CD: Where does the company currently stand in terms of funding, partnerships, or key development stages? 

JW: We are currently at the IND-enabling stage whereby we have already had a successful pre-IND meeting with the FDA which confirmed alignment on our planned GLP Toxicology studies and CMC manufacturing scale up to GMP clinical material. We are currently working to build up a syndicate to raise our Series A to close this financing which will advance our lead ViP program- VERI-101 into first-in-human clinical trials.

CD: What milestones or inflection points are most important for VerImmune in the coming months? 

JW: A key milestone is completing our Series A, which will enable full execution of our ongoing IND-enabling activities and transition VerImmune into a clinical-stage company with VERI-101 advancing into first-in-human studies.

The deadline to apply for the Innovator’s Pitch Challenge at RESI Europe has been extended to February 23. Applicants are encouraged to act quickly, as submissions are reviewed on a rolling basis.

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Europe Doesn’t Have a Capital Problem. It Has a Translation Problem 

10 Feb

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Across Europe, early-stage life science innovation isn’t held back by a lack of capital. It’s held back by a lack of translation. Brilliant ideas emerge every day from universities, startups, and labs, but too few of them cross the chasm into fundable, scalable ventures. Not because investors are uninterested, but because the signal is still forming. 

That is the gap RESI Europe is built to fill.

RESI Europe is intentionally focused on companies in the earliest stages of formation: seed, Series A, and Series B. In practical terms, that means seed financings up to $2M, Series A rounds up to $10M, and Series B rounds up to $50M. RESI is also cross-domain by design, connecting drugs, devices, diagnostics, and digital health under one roof so that cross-silo innovation can actually be seen and underwritten. These companies are not yet de-risked. They are still shaping their data, refining their narrative, and clarifying what kind of asset they are becoming. 

Unlike broad partnering events that are optimized for finished stories, RESI Europe’s product is filtration, not exposure. The investors and partners who participate specialize in early risk and engage before all the questions are answered, because that is when the partnership has the greatest leverage. And RESI does this at a registration cost typically around half of what many large European partnering conferences charge, making serious early-stage partnering accessible rather than exclusive. 

Partnering at this stage is not about acceleration.

It is about preparation. 

Europe does not need more capital flowing into the same mature assets. It needs a mechanism to translate potential into signal and the clarity to underwrite early-stage opportunities. Without that translation, meetings happen but decisions do not. Not because the science is weak, but because the story is still illegible.​ 

RESI Europe exists to make early innovation readable and to bring investors, strategics, and entrepreneurs together around the translational work that must happen before Phase II-level legibility is possible. 

Capital follows clarity.

Clarity requires translation.

That is what RESI Europe is built to deliver. 

Register for RESI Europe

Tags: , , , , , , , , , , , ,

Advancing Women’s Health Diagnostics Through Glycoproteomics: Proseek Bio at the Innovator’s Pitch Challenge 

3 Feb

Interview with Paula Cerqueira, VP of Scientific Strategy

Proseek Bio is advancing a new approach to women’s health diagnostics by translating cutting-edge glycoproteomics into clinically deployable tools. In this interview, Michelle Hill, CEO of Proseek Bio, discusses the company’s focus on ovarian cancer pre-surgical triage, the unmet clinical needs driving its platform, and how participating in the Innovator’s Pitch Challenge at RESI JPM shaped investor conversations as the company prepares for global expansion.

Michelle Hill
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): For those unfamiliar with Proseek Bio, how do you describe the company and its core technology or therapeutic focus? 

Michelle Hill (MH): Proseek Bio is an Australian diagnostics company focused on women’s health, developing blood-based tests designed to improve how complex conditions are assessed and managed in clinical practice. Ovarian cancer is our first indication, with an initial focus on pre-surgical triage.

Our platform is built on advanced glycoproteomics, integrating multiple protein biomarkers into a single algorithmic score to support clinical decision-making. Rather than relying on any one marker, this multi-analyte approach reflects the biological complexity of disease and enables more informative risk assessment at critical clinical decision points.

What differentiates Proseek Bio is our strong translational focus. The underlying science has been validated through years of academic and clinical research, and we are now converting that work into regulated, scalable diagnostic products for real-world healthcare systems. By targeting earlier decision points such as triage, we aim to support more appropriate referral and intervention, with a longer-term goal of expanding our platform across additional women’s health indications.

CD: What unmet need are you addressing, and why is now the right time for your approach? 

MH: A key unmet need in women’s health diagnostics is the lack of objective tools that reflect real-time disease biology at early clinical decision points. In ovarian cancer pre-surgical triage, clinicians must assess risk using tests with limited biological resolution, which can lead to unnecessary intervention or delayed specialist referral.

Proseek Bio addresses this gap through glycoproteomics, focusing on the glycans attached to proteins that regulate how those proteins function. While genes indicate what could happen and proteins act as messengers, glycan patterns reveal what disease is actively doing in the body. These modifications change early in cancer and cannot be resolved by genomics or standard immunoassays. By integrating glycan and protein signals into a multi-biomarker signature, our tests aim to deliver more informative risk stratification.

The timing is right because advances in clinical mass spectrometry and data analytics have made this biology clinically scalable, enabling integration into existing laboratory workflows and routine care.

CD: What was your experience participating in the Innovator’s Pitch Challenge at RESI JPM? 

MH: Our first time participating in the Innovator’s Pitch Challenge at RESI JPM was an energising experience. Pitching to a room filled with sophisticated investors and peers reinforced the importance of clear, disciplined storytelling when presenting complex diagnostic technologies.

As part of the Brisbane Economic Development Agency cohort, we were proud to represent Brisbane’s growing life sciences ecosystem. Beyond the pitch, the table showcase led to thoughtful conversations with investors and fellow founders who were genuinely engaged with both the clinical problem and our translational approach.

Overall, the experience was validating and motivating. It confirmed that our focus on clinically deployable diagnostics in women’s health resonates with a global audience, and it was rewarding to see that reflected in the recognition we received.

CD: Out of 94 Innovator’s Pitch Challenge companies, what do you think helped Proseek Bio stand out to judges and attendees? 

MH: Women’s health remains significantly underrepresented in diagnostic innovation, and that focus clearly resonated with judges and attendees. Ovarian cancer, in particular, represents a high-impact unmet need, especially at early clinical decision points such as pre-surgical triage.

Proseek Bio was the only diagnostics company on the podium, reflecting the distinctiveness of our approach. By applying glycoproteomics to analyse glycan and protein signatures together, we deliver a more biologically informative assessment of disease activity while remaining compatible with existing clinical laboratory workflows.

Importantly, we were able to clearly articulate not just the science, but the pathway to a regulated, scalable diagnostic product. That combination of unmet clinical need, novel biology, and disciplined execution helped differentiate Proseek Bio in a very strong field.

CD: How did RESI JPM impact discussions with investors, partners, or potential collaborators? 

MH: Being recognised on the Innovator’s Pitch Challenge podium gave investors immediate confidence in both the opportunity and the discipline behind the company, and it strengthened engagement with potential partners. Overall, RESI JPM acted as a signal amplifier, reinforcing Proseek Bio’s readiness for global investment and collaboration while accelerating meaningful follow-on conversations.

CD: Where does Proseek Bio currently stand in terms of fundraising, partnerships, or development milestones? 

MH: Proseek Bio is currently completing its Seed round to support development of our first product, OC-Triage. This funding is enabling a clinical study, implementation of a quality management system, and ISO accreditation to support pilot manufacturing, alongside evaluation of OC-Triage with Australian clinical laboratory partners.

In parallel, we are preparing for a Series A focused on U.S. market entry. RESI JPM provided an important opportunity to initiate discussions with U.S.-based clinical and laboratory partners, laying the groundwork for future validation and commercial pathways.

Together, these milestones reflect a transition from technology validation to execution as Proseek Bio advances toward regulated, clinically deployable diagnostics in women’s health.

CD: What upcoming achievements or milestones are you most excited to share with the life sciences community? 

MH: Over the coming year, we are focused on completing the OC-Triage product and establishing pilot manufacturing under an ISO-accredited quality system. These milestones represent an important transition from development to regulated production readiness.

In parallel, we are advancing clinical evaluation with laboratory partners, which will be critical in demonstrating real-world performance and scalability. Together, these steps mark a shift from innovation to execution.

What excites us most is seeing years of science translate into something tangible: a product that can be manufactured, validated, and ultimately used to support better clinical decisions for women.

Interested in pitching your company to a highly engaged investor audience focused on early-stage life science innovation? Applications are now open for the Innovator’s Pitch Challenge at RESI Europe. Selected companies receive direct feedback from a dedicated group of investors, access to 1:1 partnering, and visibility with global industry leaders.

Apply to pitch and position your company for meaningful investor conversations.

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

The Reality of European Global Partnering

27 Jan

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Every March, early-stage life science teams spend thousands of euros to attend one of Europe’s biggest partnering weeks. They show up expecting investors, deal momentum, and progress. Most leave with something else: lots of vendor and service provider meeting requests, and a shorter cash runway.

For seed, Series A, and early Series B companies, Lisbon is not a winter party celebration. It is a stress test. And the platforms you choose will either compound your progress or quietly drain your capital.

The Cost Reality No One Likes to Say Out Loud

Standard passes and bundled “week in Lisbon” packages routinely run from 3,000 to 5,000 euros per person, before flights and hotels. For late-stage companies, that may be acceptable. For early-stage teams living on grants, founder savings, or a small seed round, it is a major bet.

By contrast, RESI Europe is typically priced in the 1,500-2,500 euro range because it is built specifically for founders, innovators, and regional cohorts raising seed, Series A, and early Series B funding. The goal is not to sell access at any cost. It is to make high-quality global partnering economically accessible at a stage when every euro still must justify itself.

Here is the problem. Many founders pay the higher prices and then discover that a large share of their so-called “investor” meetings are with service providers selling you something. The badge may say partner or advisor, but the economics are reversed. The startup becomes the customer, not the one being backed.

That outcome is not accidental. It is how large conference ecosystems monetize scale.

Lisbon Does Not Create Strategy. It Exposes It.

Big conference weeks amplify whatever strategy you bring. If you arrive without preparation and focus, you get more noise, more meetings you did not need, and a bigger bill. If you arrive with discipline, targeted investors, and a follow-up system, Lisbon can work.

The problem is that most mega-events are optimized for volume, not readiness. More people. More meetings. More urgency. That model works for late-stage transactions. It fails early-stage teams.

Early-stage companies need fewer things done well:

  • Investors and licensing partners who write first checks
  • Fewer vendor-driven meetings
  • A way to turn first conversations into real follow-up and progress

Proof That a Different Model Works

At JPM Week in January, RESI was designed explicitly around early-stage investing. Roughly 800 companies actively seeking capital and licensing deals participated alongside more than 800 qualified investors and licensing partners from around the world.

Participation was not open-ended. Investor categories were defined. Registrations per firm were capped to protect the signal in the room. The result was not fewer meetings. It was better, more compelling meetings.

That same discipline is what matters in Lisbon.

Why the LSN Partnering Backbone Beats Scale

LSN, owner of the RESI conference series, also owns a premier database of capital investors and licensing partners in the life sciences and offers programs for de-risking early-stage assets and for preparing and executing global roadshows, as well as services like BD Assist, which actually sets up the meetings for you. RESI has five global partnering events annually.

A partnering backbone asks different questions. Are you spending time with partners who fit your stage and product? Have you reduced scientific, regulatory, and execution risk before asking for capital? Do you have a system to re-engage after the week ends? When the answer is yes, Lisbon stops being a gamble.

The Real Fight

The real battle for Lisbon is not about who has the biggest crowd or the loudest brand. It is about who is actually built for early-stage innovation and who is pricing and designing their platform around scale.

For founders, investors, and regions focused on seed, Series A, and early Series B, the smart move is to start the week with early-stage as the priority, not the afterthought, and with “investor” meaning capital and licensing partner, not a sales pitch. Plug Lisbon into a backbone that keeps working after the noise fades. That is how early-stage teams win Lisbon. And that is where the fight really is.

If You’re Coming to Lisbon

RESI Europe will take place in Lisbon with an in-person conference followed by virtual partnering, giving early-stage teams both face-to-face and online access to global investors and licensing partners at founder-level pricing. If you want your Lisbon week to start in a room built for early-stage innovation, not a room selling to you, RESI is where that week should begin.

Register for RESI Europe

Tags: , , , , , , , , , , ,

Innovator’s Pitch Challenge Spotlight: Sania Therapeutics and a Controllable Approach to Gene Therapy 

27 Jan

Interview with Paula Cerqueira, VP of Scientific Strategy

Sania Therapeutics is developing a next-generation gene therapy platform focused on treating neurological symptoms driven by dysfunctional neural circuits. At RESI London, the company was recognized as a Third-Place winner in the Innovator’s Pitch Challenge and received the highest score from the judging panel, underscoring strong investor interest in its controllable and circuit-specific approach to gene therapy. In this interview, Sania Therapeutics shares its therapeutic focus, differentiated platform, and how participation in RESI has helped shape ongoing conversations with investors and strategic partners. 

Paula Cerqueira
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): For those just discovering Sania Therapeutics, how do you describe your company and therapeutic focus?
Paula Cerqueira (PC): Sania Therapeutics is developing a new class of controllable gene therapies designed to treat neurological symptoms driven by dysfunctional neural circuits. Our platform combines localized, low-dose AAV delivery that selectively targets specific neuronal subpopulations with patient-controlled activation, allowing us to precisely modulate hyperactive neurons, improving symptoms without adversely and permanently altering normal neural function. 

Our initial therapeutic target is a motor circuit disorder: spasticity. Our broader goal is to expand into additional motor and sensory indications where current treatment options are limited, invasive, or poorly tolerated. 

CD: What unmet medical need are you addressing, and what differentiates your approach?
PC: Millions of people live with debilitating neurological symptoms such as spasticity and pain disorders, yet existing treatments are often temporary, blunt, or invasive. Oral drugs frequently cause systemic side effects, while interventions like Botox or implanted devices require repeated procedures and provide limited relief. Despite the scale of this unmet need, there has been little meaningful innovation in this area for more than a decade. 

Sania’s approach is differentiated in two key ways. First, our proprietary platform enables selective targeting of the neural circuits that drive disease using localized, low-dose AAV delivery. This approach is intended to support a safer, more sustainable, and more scalable path for gene therapy than traditional systemic delivery. 

Second, our therapy is controllable. Patients can adjust the therapeutic effect using an oral activator, allowing symptom modulation over time. This puts patients in control while enabling precise and flexible therapeutic regulation. 

Our mission at Sania is to bring gene therapy into everyday clinical use by meaningfully improving the lives of people living with neurological conditions. While this is an ambitious goal, for patients who struggle daily with basic activities such as holding a child, we believe this approach has the potential to be truly transformative. 

CD: What was your experience participating in the Innovator’s Pitch Challenge at RESI London?
PC: Participating in the Innovator’s Pitch Challenge at RESI London was an extremely valuable experience. The format encouraged clarity and discipline in how we communicated both our science and long-term vision, and the audience questions reflected a high level of engagement from investors and industry leaders. 

Being recognized as a Third Place (First Place among judges in our session) winner among a strong and diverse group of companies was particularly meaningful, and it reinforced that there is a strong interest in approaches that rethink how gene therapy can be applied beyond ultra-rare indications. 

CD: How has the RESI platform influenced conversations with investors or strategic partners?
PC: RESI offered a valuable opportunity to present our work to a broad set of investors and strategic partners and to test our messaging with a highly informed audience. While many groups are understandably focused on later-stage opportunities, the platform helped us refine our positioning and identify areas of alignment for future conversations as the company progresses. 

Following the Innovator’s Pitch Challenge, we also initiated early, informal conversations that we expect to build on as the company continues to mature. 

CD: Where does Sania Therapeutics currently stand in terms of fundraising or partnerships?
PC: Sania Therapeutics is currently focused on advancing its lead spasticity program and platform toward key preclinical and IND-enabling milestones, while continuing to expand the broader platform supporting multiple motor and sensory indications. 

In parallel, we are building relationships with investors and strategic partners aligned with our long-term vision. As the platform matures and data advances, we expect to raise funding to support clinical entry of our lead program and the continued development of additional programs enabled by the platform, and we welcome conversations with groups interested in engaging early. 

CD: What upcoming milestones are most important for the company?
PC: Our near-term focus is on advancing our lead spasticity program across regulatory and manufacturing activities and initiating IND-enabling studies in 2026. Reaching that point will significantly de-risk the program and position us well as we move this innovative approach toward the clinic. 

In parallel, we are making meaningful progress on platform development to support expansion into additional motor and sensory indications. A key goal for the team this year is to validate our first sensory capsid in vivo, leveraging the same delivery and control principles demonstrated in our lead program. 

Applications are now open for the Innovator’s Pitch Challenge at RESI Europe. Life science and health tech companies seeking targeted feedback from a dedicated group of coordinated investors are encouraged to apply to participate in interactive pitching, partnering, and one-to-one meetings at RESI Europe. 

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Proseek Bio claims global bronze in San Francisco, strengthening Brisbane’s MedTech credentials 

27 Jan

Brisbane’s world renowned MedTech sector has again been recognised on the global stage, with local company Proseek Bio securing bronze at the Innovator’s Pitch Challenge during J.P. Morgan Healthcare Week in San Francisco. 

Proseek Bio, a participant in Brisbane Economic Development Agency’s MedTech Global Accelerator, competed against more than 90 international health technology companies and was recognised for its groundbreaking work in non-invasive blood tests aimed at earlier and more accurate detection of ovarian cancer, an area of significant unmet global health need. 

This year’s achievement continues Brisbane’s strong run of podium success at one of the world’s most influential healthcare investor forums, highlighting the city’s growing capability to develop, commercialise and scale life-changing medical technologies. 

Brisbane’s Innovator’s Pitch Challenge podium finishes include: 

  • 2023 Gold: Field Orthopaedics; Bronze: Max Kelsen 
  • 2024 Silver: Convergence Medical; Bronze: Gelomics 
  • 2025 Gold: Kimaritec 
  • 2026 Bronze: Proseek Bio 

BEDA’s MedTech Global Accelerator cohort attended the RESI JPM 2026 Investor Forum, in partnership with Life Science Nation, a leading US investor and life sciences networking platform. 

Lord Mayor Adrian Schrinner said the result was another strong sign of Brisbane’s rising reputation in health and medical innovation. 

“Brisbane’s MedTech talent continues to make waves on the world stage,” Cr Schinner said. 

“Proseek Bio’s bronze finish shows just how much innovation is coming out of our city and that Brisbane can go toe-to-toe with the best in the world – especially in lifesaving areas like women’s health and cancer detection. 

“We’re proud to support our innovators in building the global connections and partnerships they need to turn great ideas into reality.” 

Proseek Bio Founder and CEO, Professor Michelle Hill said the recognition marked a significant milestone for the company. 

“Winning bronze in this highly competitive challenge is a tremendous achievement for us,” Professor Hill said. 

“It validates the potential of our technology to make a real difference in women’s health and accelerates our ability to attract global partners and investment. 

“Support through BEDA’s MedTech Global Accelerator and its international network has been critical to our journey.” 

Now in its fourth year, the accelerator has helped more than 30 visionary companies secure $246 million in capital and create more than 250 jobs in Brisbane.  

BEDA’s FY26 MedTech Global Accelerator cohort included Aptium AI, BiVACOR, Cool Beans Underwear, Fibrosoft, Ketim Technologies, LORAI Health, Proseek Bio, QBiotics Group Limited, STARCO and Talius. 

For more information about the MedTech Initiative, visit https://choose.brisbane.qld.au/business/key-industries/health/medtech 

Tags: , , , , , , , , ,

RESI 2026: Sponsorship That Delivers Visibility, Connection, and Real Engagement 

21 Jan

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

The RESI (Redefining Every Stage of Investment) Conference Series, produced by Life Science Nation (LSN), has become a cornerstone event series for the early-stage life science ecosystem. Designed to bring together innovators, investors, and strategic partners, RESI offers a highly curated environment where capital formation, partnership development, and brand visibility intersect.

In 2026, the RESI Series continues its global reach through a combination of in-person conferences and structured virtual partnering, offering sponsors year-round exposure and repeated touchpoints with a highly targeted audience.

A Global Series Built for Impact

The 2026 RESI Series includes multiple events across major life science hubs:

  • RESI Europe 2026 – Lisbon, March 23 (with virtual partnering March 24–25)
  • RESI June at San Diego 2026 – June 22 (with virtual partnering June 23–24, 29)
  • RESI Boston 2026 – September 22–23 (with follow-up virtual partnering September 25, 28)

Across these events, RESI convenes companies spanning therapeutics, diagnostics, medical devices, digital health, and enabling technologies, alongside venture capital firms, family offices, strategic investors, and corporate partners. Sponsors benefit from consistent brand presence across the series while engaging with a community focused on early-stage innovation and investment readiness.

Why Organizations Sponsor RESI

RESI sponsorship is structured to go beyond logo placement. Sponsors are integrated into the fabric of the conference experience, with benefits that can include:

  • High-visibility branding across pre-event marketing, onsite signage, and digital platforms
  • Exhibit opportunities in high-traffic networking areas during in-person events
  • Thought-leadership placement, including workshops, moderated sessions, and published articles distributed to LSN’s global audience
  • Targeted networking and partnering, supported by RESI’s proprietary matchmaking platform
  • Post-event attendee access, enabling meaningful follow-up with investors, founders, and decision-makers

Tiered sponsorship options allow organizations to align their level of involvement with specific business development, visibility, or ecosystem-building goals, while optional add-ons provide further customization.

Who Benefits from Sponsoring RESI

RESI sponsorship is designed to support a wide range of organizations across the life science ecosystem. Sponsors consistently report value not only in exposure, but in the relevance and quality of connections made.

Service Providers
CROs, CDMOs, legal, IP, regulatory, manufacturing, data, and commercialization services (e.g., McDermot Will & Emery, Biometas)

  • Direct access to early-stage companies actively building pipelines and seeking partners
  • Visibility among founders, executives, and investors at key decision-making stages
  • Opportunities to demonstrate expertise through workshops, articles, and curated sessions

Organizations such as Medmarc exemplify the value of sustained participation. Their consistent presence across multiple RESI conferences has helped establish familiarity and trust with early-stage companies, positioning them as a known and credible partner as those companies progress from formation through later stages of growth.

Regional Organizations and Innovation Hubs
Economic development groups, accelerators, incubators, trade organizations, and government-backed initiatives (past sponsors include Brisbane Economic Development Agency (BEDA), Kobe Biomedical Innovation Cluster, (KBIC) and Israel Export Institute (IEI))

  • A global platform to showcase regional ecosystems and portfolio companies
  • The ability to host demo days, pitch sessions, or dedicated tracks aligned with regional priorities
  • Increased international exposure to investors and strategic partners

Investors and Strategic and Corporate Partners
Venture capital, corporate venture, family offices, and strategic partners (past sponsors include, Muscular Dystrophy Association (MDA), Johnson & Johnson Innovation JLABS, and Eli Lilly)

  • Targeted visibility among investment- or partnering-ready startups across multiple modalities
  • Access to curated partnering and company intelligence through the RESI platform
  • Opportunities to participate in panels, pitch sessions, and thought-leadership programming
  • Structured environments for scouting, relationship-building, and ecosystem engagement
  • Brand alignment with a trusted, innovation-focused conference series

Sponsor Spotlight: How Organizations Activated Their Presence at RESI JPM 2026

While RESI JPM 2026 has already taken place, it provides a strong example of how sponsors can actively engage with the RESI platform — not just through visibility, but through programming and participation that creates tangible value.

One notable example is Kobe Biomedical Innovation Cluster (KBIC), a Gold Sponsor of RESI JPM 2026. KBIC leveraged its sponsorship to host the Kansai Life Sciences Accelerator Program (KLSAP) Demo Day, a dedicated session that highlighted emerging life science companies from its accelerator cohort.

Through this activation, KBIC provided startups with direct access to international investors and strategic partners, while reinforcing its role as a global connector within the life science innovation ecosystem. Rather than serving as a passive sponsor, KBIC used the RESI platform to advance its mission, support portfolio companies, and foster cross-border collaboration.

Similarly, Trillium BIO capitalized on both the high foot traffic generated by its exhibit booth and RESI’s partnering platform to schedule a large number of targeted meetings for its team. By combining in-person visibility with structured partnering, Trillium BIO maximized engagement efficiency and ensured meaningful conversations with potential clients and partners throughout the event.

What Successful Sponsors Do Differently

Examples from RESI JPM illustrate several effective sponsorship strategies that carry forward across the 2026 Series:

They integrate into the program.
Sponsors that host workshops, demo days, or curated sessions create natural engagement opportunities and attract aligned audiences.

They align sponsorship with strategy.
Whether the goal is pipeline development, geographic expansion, or investor visibility, effective sponsors use RESI to support broader organizational objectives.

They prioritize connection over exposure alone.
By leveraging partnering tools, curated meetings, and live engagement opportunities, sponsors maximize the quality of interactions — not just the quantity.

Looking Ahead

As the RESI 2026 Series continues across Europe and the United States, sponsors can build sustained visibility while actively shaping conversations at the forefront of life science innovation. The success of sponsor activations at past events demonstrates that RESI is not simply a conference series but a platform for meaningful engagement, partnership building, and long-term impact within the global life science community.

For more information about sponsorship opportunities across the RESI 2026 Series, contact us at sales@lifesciencenation.com. We look forward to discussing your needs and exploring how RESI can support your goals.

Tags: , , , , , , , , , , , , , , , , , , , , ,

← Older Entries